188 related articles for article (PubMed ID: 33254497)
1. A legendary sumo wrestler with gigantism or acromegaly? The case of Ikezuki Geitazaemon (1827-1850).
Takada K; Sasano M; Hayakawa S
Med Hypotheses; 2020 Nov; 144():110174. PubMed ID: 33254497
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous remission of acromegaly or gigantism due to subclinical apoplexy of pituitary growth hormone adenoma.
Wang XL; Dou JT; Lü ZH; Zhong WW; Ba JM; Jin D; Lu JM; Pan CY; Mu YM
Chin Med J (Engl); 2011 Nov; 124(22):3820-3. PubMed ID: 22340248
[TBL] [Abstract][Full Text] [Related]
4. Genetics of gigantism and acromegaly.
Hannah-Shmouni F; Trivellin G; Stratakis CA
Growth Horm IGF Res; 2016; 30-31():37-41. PubMed ID: 27657986
[TBL] [Abstract][Full Text] [Related]
5. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
Bondanelli M; Bonadonna S; Ambrosio MR; Doga M; Gola M; Onofri A; Zatelli MC; Giustina A; degli Uberti EC
Metabolism; 2005 Sep; 54(9):1174-80. PubMed ID: 16125529
[TBL] [Abstract][Full Text] [Related]
6. Potential markers of disease behavior in acromegaly and gigantism.
Hernández-Ramírez LC
Expert Rev Endocrinol Metab; 2020 May; 15(3):171-183. PubMed ID: 32372673
[No Abstract] [Full Text] [Related]
7. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of pituitary gigantism.
Cunha C; Saraiva C; Canas Marques C; Duarte JS
BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34972788
[TBL] [Abstract][Full Text] [Related]
9. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
10. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
11. Familial gigantism.
Herder WW
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):29-32. PubMed ID: 22584702
[TBL] [Abstract][Full Text] [Related]
12. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
Schwyzer L; Starke RM; Jane JA; Oldfield EH
J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
[TBL] [Abstract][Full Text] [Related]
13. 'Silent' somatotropinoma.
Pawlikowski M; Kuta J; Fuss-Chmielewska J; Winczyk K
Endokrynol Pol; 2012; 63(2):88-91. PubMed ID: 22538745
[TBL] [Abstract][Full Text] [Related]
14. [Old phenotype and new genotypes. Pituitary adenomas].
Gérard C; Jedidi H; Petrossians P; Krzesinski F; Daly A; Beckers A
Rev Med Liege; 2015 Nov; 70(11):569-74. PubMed ID: 26738269
[TBL] [Abstract][Full Text] [Related]
15. [Acromegaly and it's cardiovascular implications].
Cadena-Obando DA; Remba-Shapiro I; Abreu-Rosario CG; Mercado M
Rev Med Inst Mex Seguro Soc; 2021 Feb; 59(1):73-80. PubMed ID: 33667046
[TBL] [Abstract][Full Text] [Related]
16. Investigation into the efficacy and safety of octreotide LAR in Japanese patients with acromegaly: Shizuoka study.
Oki Y; Inoue T; Imura M; Tanaka T; Genma R; Iwabuchi M; Hataya Y; Matsuzawa Y; Iino K; Nishizawa S; Nakamura H
Endocr J; 2009; 56(9):1095-101. PubMed ID: 19755754
[TBL] [Abstract][Full Text] [Related]
17. [Gigantism: a mystery explained].
Beckers A
Bull Mem Acad R Med Belg; 2002; 157(1-2):111-7; discussion 117-9. PubMed ID: 12371275
[TBL] [Abstract][Full Text] [Related]
18. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
[TBL] [Abstract][Full Text] [Related]
19. Large-scale second-hit AIP deletion causing a pediatric growth hormone-secreting pituitary adenoma: Case report and review of literature.
Gummadavelli A; Dinauer C; McGuone D; Vining EM; Erson-Omay EZ; Omay SB
J Clin Neurosci; 2020 Aug; 78():420-422. PubMed ID: 32336638
[TBL] [Abstract][Full Text] [Related]
20. AIP mutation in pituitary adenomas in the 18th century and today.
Chahal HS; Stals K; Unterländer M; Balding DJ; Thomas MG; Kumar AV; Besser GM; Atkinson AB; Morrison PJ; Howlett TA; Levy MJ; Orme SM; Akker SA; Abel RL; Grossman AB; Burger J; Ellard S; Korbonits M
N Engl J Med; 2011 Jan; 364(1):43-50. PubMed ID: 21208107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
